Verjans Johan W, Osborn Eric A, Ughi Giovanni J, Calfon Press Marcella A, Hamidi Ehsan, Antoniadis Antonios P, Papafaklis Michail I, Conrad Mark F, Libby Peter, Stone Peter H, Cambria Richard P, Tearney Guillermo J, Jaffer Farouc A
Cardiovascular Research Center, Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts; Department of Cardiology, University Medical Center Utrecht, Utrecht, the Netherlands.
Cardiovascular Research Center, Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts; Cardiology Division, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
JACC Cardiovasc Imaging. 2016 Sep;9(9):1087-1095. doi: 10.1016/j.jcmg.2016.01.034. Epub 2016 Aug 17.
This study sought to determine whether indocyanine green (ICG)-enhanced near-infrared fluorescence (NIRF) imaging can illuminate high-risk histologic plaque features of human carotid atherosclerosis, and in coronary atheroma of living swine, using intravascular NIRF-optical coherence tomography (OCT) imaging.
New translatable imaging approaches are needed to identify high-risk biological signatures of atheroma. ICG is a U.S. Food and Drug Administration-approved NIRF imaging agent that experimentally targets plaque macrophages and lipid in areas of enhanced endothelial permeability. However, it is unknown whether ICG can target atheroma in patients.
Eight patients were enrolled in the BRIGHT-CEA (Indocyanine Green Fluorescence Uptake in Human Carotid Artery Plaque) trial. Five patients were injected intravenously with ICG 99 ± 25 min before clinically indicated carotid endarterectomy. Three saline-injected endarterectomy patients served as control subjects. Excised plaques underwent analysis by intravascular NIRF-OCT, reflectance imaging, microscopy, and histopathology. Next, following ICG intravenous injection, in vivo intracoronary NIRF-OCT and intravascular ultrasound imaged 3 atheroma-bearing coronary arteries of a diabetic, cholesterol-fed swine.
ICG was well tolerated; no adverse clinical events occurred up to 30 days post-injection. Multimodal NIRF imaging including intravascular NIRF-OCT revealed that ICG accumulated in all endarterectomy specimens. Plaques from saline-injected control patients exhibited minimal NIRF signal. In the swine experiment, intracoronary NIRF-OCT identified ICG uptake in all intravascular ultrasound-identified plaques in vivo. On detailed microscopic evaluation, ICG localized to plaque areas exhibiting impaired endothelial integrity, including disrupted fibrous caps, and within areas of neovascularization. Within human plaque areas of endothelial abnormality, ICG was spatially related to localized zones of plaque macrophages and lipid, and, notably, intraplaque hemorrhage.
This study demonstrates that ICG targets human plaques exhibiting endothelial abnormalities and provides new insights into its targeting mechanisms in clinical and experimental atheroma. Intracoronary NIRF-OCT of ICG may offer a novel, clinically translatable approach to image pathobiological aspects of coronary atherosclerosis. (Indocyanine Green Fluorescence Uptake in Human Carotid Artery Plaque [BRIGHT-CEA]; NCT01873716).
本研究旨在确定吲哚菁绿(ICG)增强的近红外荧光(NIRF)成像是否能够通过血管内NIRF-光学相干断层扫描(OCT)成像,揭示人类颈动脉粥样硬化以及活体猪冠状动脉粥样硬化的高危组织学斑块特征。
需要新的可转化成像方法来识别动脉粥样硬化的高危生物学特征。ICG是一种经美国食品药品监督管理局批准的NIRF成像剂,在实验中可靶向内皮通透性增强区域的斑块巨噬细胞和脂质。然而,ICG是否能在患者中靶向动脉粥样硬化尚不清楚。
8名患者参与了BRIGHT-CEA(吲哚菁绿在人类颈动脉斑块中的荧光摄取)试验。5名患者在临床指示的颈动脉内膜切除术前行静脉注射ICG,时间为99±25分钟。3名注射生理盐水的内膜切除术患者作为对照。对切除的斑块进行血管内NIRF-OCT、反射成像、显微镜检查和组织病理学分析。接下来,在静脉注射ICG后,对一只糖尿病、高脂喂养猪体内3条有动脉粥样硬化的冠状动脉进行体内冠状动脉NIRF-OCT和血管内超声成像。
ICG耐受性良好;注射后30天内未发生不良临床事件。包括血管内NIRF-OCT在内的多模态NIRF成像显示,ICG在所有内膜切除标本中均有积聚。注射生理盐水的对照患者的斑块显示出最小的NIRF信号。在猪实验中,体内冠状动脉NIRF-OCT识别出所有血管内超声识别的斑块中均有ICG摄取。在详细的显微镜评估中,ICG定位于内皮完整性受损的斑块区域,包括破裂的纤维帽以及新生血管区域内。在人类内皮异常的斑块区域内,ICG在空间上与斑块巨噬细胞和脂质的局部区域相关,尤其是斑块内出血区域。
本研究表明,ICG可靶向表现出内皮异常的人类斑块,并为其在临床和实验性动脉粥样硬化中的靶向机制提供了新的见解。ICG的冠状动脉内NIRF-OCT可能为冠状动脉粥样硬化的病理生物学方面成像提供一种新的、可临床转化的方法。(吲哚菁绿在人类颈动脉斑块中的荧光摄取[BRIGHT-CEA];NCT01873716)